المؤلفون: Henk L. Dekker, Elisa Giovannetti, Marcello Tiseo, Patrick Pauwels, Filip Lardon, Christian Rolfo, Kaylee Keller, Rob Ruijtenbeek, Alessandro Leonetti, Niccola Funel, Godefridus J. Peters, Nele Van Der Steen

المساهمون: Medical oncology laboratory, AGEM - Re-generation and cancer of the digestive system, CCA - Cancer biology and immunology

المصدر: Biochemical pharmacology
van der Steen, N, Leonetti, A, Keller, K, Dekker, H, Funel, N, Lardon, F, Ruijtenbeek, R, Tiseo, M, Rolfo, C, Pauwels, P, Peters, G J & Giovannetti, E 2019, ' Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line ', Biochemical Pharmacology, vol. 166, pp. 128-138 . https://doi.org/10.1016/j.bcp.2019.05.014Test
Biochemical Pharmacology, 166, 128-138. Elsevier Inc.

مصطلحات موضوعية: 0301 basic medicine, MAPK/ERK pathway, Male, Lung Neoplasms, Antineoplastic Agents, Biochemistry, 03 medical and health sciences, Erlotinib Hydrochloride, 0302 clinical medicine, Crizotinib, Carcinoma, Non-Small-Cell Lung, Cell Line, Tumor, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Epidermal growth factor receptor, Phosphorylation, Lung cancer, Protein kinase B, PI3K/AKT/mTOR pathway, Adaptor Proteins, Signal Transducing, Aged, Pharmacology, biology, Chemistry, Pharmacology. Therapy, Drug Synergism, Cell cycle, Middle Aged, Proto-Oncogene Proteins c-met, medicine.disease, ErbB Receptors, 030104 developmental biology, 030220 oncology & carcinogenesis, Cancer research, biology.protein, Female, Erlotinib, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::198c1da7976161631dcc7ca088486798Test
https://hdl.handle.net/10067/1611930151162165141Test

المؤلفون: C. J. van Groeningen, Elisa Giovannetti, G.J. Peters, R. Ruijter, Henk M.W. Verheul, Giuseppe Giaccone, A. A. van Zweeden, Richard J. Honeywell, Carolien H. Smorenburg, Hans J. van der Vliet

المساهمون: Medical oncology, Medical oncology laboratory, AGEM - Re-generation and cancer of the digestive system, CCA - Cancer Treatment and quality of life

المصدر: van Zweeden, A A, van Groeningen, C J, Honeywell, R J, Giovannetti, E, Ruijter, R, Smorenburg, C H, Giaccone, G, Verheul, H M W, Peters, G J & van der Vliet, H J 2018, ' Randomized phase 2 study of gemcitabine and cisplatin with or without vitamin supplementation in patients with advanced esophagogastric cancer ', Cancer Chemotherapy and Pharmacology, vol. 82, no. 1, pp. 39-48 . https://doi.org/10.1007/s00280-018-3588-6Test
Cancer Chemotherapy and Pharmacology
Cancer Chemotherapy and Pharmacology, 82(1), 39-48. Springer Verlag

مصطلحات موضوعية: 0301 basic medicine, Adult, Male, Cancer Research, medicine.medical_specialty, Folic acid, Esophageal Neoplasms, Esophagogastric cancer, Cmax, Phases of clinical research, Adenocarcinoma, Toxicology, Gastroenterology, Deoxycytidine, 03 medical and health sciences, 0302 clinical medicine, Stomach Neoplasms, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Clinical endpoint, Humans, Pharmacology (medical), Vitamin B12, Aged, Pharmacology, Cisplatin, Aged, 80 and over, business.industry, Drug Synergism, Middle Aged, medicine.disease, Gemcitabine, Vitamin B 12, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Toxicity, Dietary Supplements, Original Article, Female, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2502b3d61670f51491c3457468559503Test
https://research.vumc.nl/en/publications/2bf1b93c-372d-48e0-ac96-fc8c6c2699d3Test

المؤلفون: S. Caponi, Elisa Paolicchi, Daniela Campani, Pinuccia Faviana, Elisa Giovannetti, Godefridus J. Peters, Niccola Funel, Ugo Boggi, Amir Avan, Paola Pacetti, Enrico Vasile, Michele Reni, Mina Maftouh, Andrea Mambrini, Michele Milella, Vanja Vaccaro, Maurizio Cantore

المساهمون: Medical oncology laboratory, CCA - Innovative therapy

المصدر: Maftouh, M, Avan, A, Funel, N, Paolicchi, E, Vasile, E, Pacetti, P, Vaccaro, V, Faviana, P, Campani, D, Caponi, S, Mambrini, A, Boggi, U, Cantore, M, Milella, M, Peters, G J, Reni, M & Giovannetti, E 2014, ' A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patients ', Pharmacogenomics, vol. 15, no. 5, pp. 609-618 . https://doi.org/10.2217/pgs.13.225Test
Università di Pisa-IRIS
Pharmacogenomics, 15(5), 609-618. Future Medicine Ltd.

مصطلحات موضوعية: Male, Antimetabolites, Antineoplastic, Prognostic factor, Pancreatic ductal adenocarcinoma, Antimetabolites, Locally advanced, macromolecular substances, Deoxycytidine, Promoter Regions, Cohort Studies, Genetic, Pancreatic cancer, Genetics, medicine, Humans, SNP, Enhancer of Zeste Homolog 2 Protein, Polymorphism, Promoter Regions, Genetic, Aged, Pharmacology, Polymorphism, Genetic, business.industry, EZH2, Polycomb Repressive Complex 2, DNA, Middle Aged, medicine.disease, Antineoplastic, Survival Analysis, Gemcitabine, Pancreatic Neoplasms, MicroRNAs, Treatment Outcome, Cohort, Disease Progression, Cancer research, Molecular Medicine, Female, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4bc8f783cd084710d92d4ab8ad3e724eTest
https://doi.org/10.2217/pgs.13.225Test

المؤلفون: Richard J. Honeywell, Joseph Ciccolini, Nienke Losekoot, Cindy Serdjebi, M. Maulandi, M.C. Etienne-Grimaldi, Elisa Giovannetti, G.J. Peters, G. Milano

المساهمون: Medical oncology laboratory, CCA - Innovative therapy

المصدر: Nucleosides, Nucleotides and Nucleic Acids, 33(4-6), 403-412. Taylor and Francis Ltd.
Peters, G J, Honeywell, R J, Maulandi, M, Giovannetti, E, Losekoot, N, Etienne-Grimaldi, M C, Milano, G, Serdjebi, C & Ciccolini, J 2014, ' Selection of the Best Blood Compartment to Measure Cytidine Deaminase Activity to Stratify for Optimal Gemcitabine Or Cytarabine Treatment ', Nucleosides, Nucleotides and Nucleic Acids, vol. 33, no. 4-6, pp. 403-412 . https://doi.org/10.1080/15257770.2014.894196Test

مصطلحات موضوعية: Adult, Male, Cytidine deaminase activity, Cost-Benefit Analysis, Pharmacology, Biochemistry, Deoxycytidine, chemistry.chemical_compound, Young Adult, Cytidine Deaminase, Genetics, medicine, Humans, Dosing, Whole blood, Enzyme Assays, Chemistry, Cytarabine, Reproducibility of Results, Cytidine, General Medicine, Cytidine deaminase, Middle Aged, Gemcitabine, Toxicity, Molecular Medicine, Female, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc886224b3c27ee84817938ec30aa529Test
https://doi.org/10.1080/15257770.2014.894196Test

المؤلفون: Jacobus A. Burgers, Godefridus J. Peters, Egbert F. Smit, Elisa Giovannetti, Francesco Di Costanzo, Andrea Ardizzoni, Carmelo Tibaldi, Andrea Camerini, Fausto Barbieri, Marcello Tiseo, Andrew D. Vincent

المساهمون: Medical oncology laboratory, Pulmonary medicine, CCA - Innovative therapy, Tiseo, Marcello, Giovannetti, Elisa, Tibaldi, Carmelo, Camerini, Andrea, Di Costanzo, Francesco, Barbieri, Fausto, Burgers, Jacobus A., Vincent, Andrew, Peters, Godefridus J., Smit, Egbert F., Ardizzoni, Andrea

المصدر: Lung Cancer, 78(1), 92-99. Elsevier Ireland Ltd
Tiseo, M, Giovannetti, E, Tibaldi, C, Camerini, A, Di Costanzo, F, Barbieri, F, Burgers, J A, Vincent, A D, Peters, G J, Smit, E F & Ardizzoni, A 2012, ' Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin ', Lung Cancer, vol. 78, no. 1, pp. 92-99 . https://doi.org/10.1016/j.lungcan.2012.07.009Test

مصطلحات موضوعية: Male, Oncology, Cancer Research, Lung Neoplasms, non-small cell lung cancer (NSCLC), Pharmacology, Thymidylate synthase, Carboplatin, Antineoplastic Agent, Reduced Folate Carrier Protein, chemistry.chemical_compound, Gene Frequency, Glutamates, Retrospective Studie, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, Allele, Aged, 80 and over, biology, Pharmacogenetic, Hazard ratio, Middle Aged, Treatment Outcome, Pemetrexed, Female, Glutamate, Human, medicine.drug, Adult, Pulmonary and Respiratory Medicine, medicine.medical_specialty, Guanine, Genotype, Non-small cell lung cancer (NSCLC), Antineoplastic Agents, Polymorphism, Single Nucleotide, Internal medicine, medicine, Humans, Alleles, Methylenetetrahydrofolate Reductase (NADPH2), Aged, Neoplasm Staging, Retrospective Studies, Xeroderma Pigmentosum Group D Protein, Antineoplastic Combined Chemotherapy Protocol, business.industry, Proportional hazards model, Thymidylate Synthase, gamma-Glutamyl Hydrolase, MTHFR-C667T polymorphism, medicine.disease, Lung Neoplasm, chemistry, Methylenetetrahydrofolate reductase, biology.protein, business, Pharmacogenetics

وصف الملف: ELETTRONICO

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e75b870f6ebcd4b15db069e24f07cf1Test
https://doi.org/10.1016/j.lungcan.2012.07.009Test

المؤلفون: Stefano Fogli, Elisa Giovannetti, F. de Braud, Romano Danesi, Giuseppe Curigliano, T. De Pas, M. Del Tacca

المساهمون: Medical oncology laboratory, AGEM - Re-generation and cancer of the digestive system, CCA - Cancer biology and immunology, CCA - Imaging and biomarkers, CCA - Cancer Treatment and quality of life, AII - Cancer immunology

المصدر: Fogli, S, Danesi, R, Braud, F D, Pas, T D, Curigliano, G, Giovannetti, E & Tacca, M D 2001, ' Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer ', Annals of Oncology, vol. 12, no. 11, pp. 1553-1559 . https://doi.org/10.1023/A:1013133415945Test
Annals of Oncology, 12(11), 1553-1559. Oxford University Press

مصطلحات موضوعية: Adult, Lung Neoplasms, Adolescent, Paclitaxel, medicine.medical_treatment, Cmax, Phases of clinical research, Pharmacology, Deoxycytidine, chemistry.chemical_compound, Pharmacokinetics, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Distribution (pharmacology), Infusions, Intravenous, Chromatography, High Pressure Liquid, Aged, Chemotherapy, Dose-Response Relationship, Drug, business.industry, Hematology, Middle Aged, Gemcitabine, Oncology, chemistry, Area Under Curve, Pharmacodynamics, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23ad3167ac399acc3188842b8ae4949fTest
http://www.scopus.com/inward/record.url?scp=0035690123&partnerID=8YFLogxKTest

المؤلفون: Clara Lemos, Gl Scheffer, G. Giaccone, Elisa Giovannetti, Carmelo Tibaldi, G.J. Peters, T. van der Straaten, H-J Guchelaar, Pa Zucali, Alfredo Falcone, Armando Santoro, Yg Assaraf, Romano Danesi, Armida D'Incecco

المساهمون: Medical oncology, Medical oncology laboratory, Pathology, CCA - Innovative therapy

المصدر: Pharmacogenomics, 12(2), 159-170
Lemos, C, Giovannetti, E, Zucali, P A, Assaraf, Y G, Scheffer, G L, van der Straaten, T, D'Incecco, A, Falcone, A, Guchelaar, H J, Danesi, R, Santoro, A, Giaccone, G, Tibaldi, C & Peters, G J 2011, ' Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients ', Pharmacogenomics, vol. 12, no. 2, pp. 159-170 . https://doi.org/10.2217/pgs.10.172Test
Pharmacogenomics
Pharmacogenomics, 12(2), 159-170. Future Medicine Ltd.

مصطلحات موضوعية: Male, Oncology, Lung Neoplasms, Abcg2, gefitinib, Genome-wide association study, NSCLC, Carcinoma, Non-Small-Cell Lung, Genotype, ATP Binding Cassette Transporter, Subfamily G, Member 2, Precision Medicine, pharmacogenetics, biology, Middle Aged, Neoplasm Proteins, Treatment Outcome, embryonic structures, Toxicity, Molecular Medicine, Female, medicine.drug, Diarrhea, medicine.medical_specialty, ABCG2, animal structures, Antineoplastic Agents, Article, Gefitinib, Internal medicine, Genetics, medicine, Humans, Lung cancer, Pharmacology, Polymorphism, Genetic, business.industry, Haplotype, toxicity, medicine.disease, respiratory tract diseases, lung cancer, Haplotypes, Quinazolines, Cancer research, biology.protein, ATP-Binding Cassette Transporters, sense organs, business, Pharmacogenetics, Genome-Wide Association Study

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89d8dbdb68ab3323182687faf44033e8Test
https://doi.org/10.2217/pgs.10.172Test

المؤلفون: Elisa Giovannetti, Godefridus J. Peters, Leticia G. Leon, Niccola Funel, Stefano Cereda, Matteo Lucchesi, Michele Reni, Maurizio Cantore, Andrea Mambrini, Michele Ghidini, Paola Pacetti, Enrico Vasile

المساهمون: Giovannetti, E, Pacetti, P, Reni, M, Leon, Lg, Mambrini, A, Vasile, E, Ghidini, M, Funel, N, Lucchesi, M, Cereda, S, Peters, Gj, Cantore, M, Medical oncology laboratory, CCA - Innovative therapy

المصدر: Pharmacogenomics, 12(12), 1641-1652. Future Medicine Ltd.
Giovannetti, E, Pacetti, P, Reni, M, Leon, L G, Mambrini, A, Vasile, E, Ghidini, M, Funel, N, Lucchesi, M, Cereda, S, Peters, G J & Cantore, M 2011, ' Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy ', Pharmacogenomics, vol. 12, no. 12, pp. 1641-1652 . https://doi.org/10.2217/PGS.11.109Test

مصطلحات موضوعية: Oncology, Male, medicine.medical_specialty, DNA Repair, Docetaxel, Kaplan-Meier Estimate, Pharmacology, Polymorphism, Single Nucleotide, Disease-Free Survival, Capecitabine, Pancreatic cancer, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Genetics, medicine, Humans, Genetic Association Studies, Aged, Neoplasm Staging, Xeroderma Pigmentosum Group D Protein, Cisplatin, business.industry, Hazard ratio, Combination chemotherapy, Middle Aged, medicine.disease, Prognosis, Gemcitabine, Pancreatic Neoplasms, DNA Repair Enzymes, Drug Resistance, Neoplasm, Molecular Medicine, Female, Taxoids, business, medicine.drug, Epirubicin

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09486a5ac41acd8ee96d4e5b5d9520eeTest

المؤلفون: Ilaria Pastina, Sergio Ricci, Tristan M. Sissung, Romano Danesi, Douglas K. Price, William D. Figg, Cinzia Orlandini, Aldo Chioni, C. Cianci, Francesco Crea, Elisa Giovannetti

المساهمون: Medical oncology laboratory, CCA - Innovative therapy

المصدر: BMC Cancer, 10. BioMed Central
BMC Cancer
Pastina, I, Giovannetti, E, Chioni, A, Sissung, T M, Crea, F, Orlandini, C, Price, D K, Cianci, C, Figg, W D, Ricci, S & Danesi, R 2010, ' Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients ', BMC Cancer, vol. 10, pp. 511 . https://doi.org/10.1186/1471-2407-10-511Test
BMC Cancer, Vol 10, Iss 1, p 511 (2010)

مصطلحات موضوعية: Oncology, Male, medicine.medical_specialty, Cancer Research, Genotype, medicine.medical_treatment, CYP1B1, Antineoplastic Agents, Pharmacology, lcsh:RC254-282, Prostate cancer, Surgical oncology, Internal medicine, medicine, Genetics, Humans, pharmacogenetics, docetaxel, prostate cancer, Aged, Aged, 80 and over, Chemotherapy, Predictive marker, Polymorphism, Genetic, business.industry, Prostatic Neoplasms, Middle Aged, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Regimen, Treatment Outcome, Docetaxel, Drug Resistance, Neoplasm, Cytochrome P-450 CYP1B1, Multivariate Analysis, Taxoids, Aryl Hydrocarbon Hydroxylases, business, Pharmacogenetics, medicine.drug, Research Article

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8d4b7502b090bab3a294e49896ddfdcTest
https://research.vumc.nl/en/publications/e3d52b71-e2c3-4422-b169-fb26d797e27bTest

المؤلفون: Generoso Bevilacqua, Luca Pollina, Elisa Giovannetti, Sara Nannizzi, Franco Mosca, Valentina Mey, Mario Del Tacca, Romano Danesi, Niccola Funel, S. Ricciardi, Daniela Campani, Marco Del Chiaro, Ugo Boggi

المساهمون: Medical oncology laboratory, CCA - Disease profiling

المصدر: Laboratory Investigation, 88(7), 773-784. Nature Publishing Group
Funel, N, Giovannetti, E, Del Chiaro, M, Mey, V, Pollina, L E, Nannizzi, S, Boggi, U, Ricciardi, S, Del Tacca, M, Bevilacqua, G, Mosca, F, Danesi, R & Campani, D 2008, ' Laser microdissection and primary cell cultures improve pharmacogenetic analysis in pancreatic adenocarcinoma ', Laboratory Investigation, vol. 88, no. 7, pp. 773-784 . https://doi.org/10.1038/labinvest.2008.40Test

مصطلحات موضوعية: Male, Pathology, Messenger, Tetrazolium Salts, Deoxycytidine, Gene expression, 80 and over, Tumor Markers, Microdissection, Cells, Cultured, Laser capture microdissection, Oligonucleotide Array Sequence Analysis, Aged, 80 and over, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, pharmacology, Carcinoma, Pancreatic Ductal, metabolism/pathology, Cells, Cultured, Deoxycytidine, analogs /&/ derivatives/pharmacology, Female, Fluorouracil, pharmacology, Humans, Lasers, Male, Microdissection, methods, Middle Aged, Oligonucleotide Array Sequence Analysis, Pancreatic Neoplasms, metabolism/pathology, RNA, biosynthesis/isolation /&/ purification, Tetrazolium Salts, pharmacology, Thiazoles, pharmacology, Tumor Markers, Biological, metabolism, Cultured, Middle Aged, Primary tumor, Real-time polymerase chain reaction, Adenocarcinoma, Female, Fluorouracil, biosynthesis/isolation /&/ purification, Carcinoma, Pancreatic Ductal, metabolism/pathology, Adult, medicine.medical_specialty, Stromal cell, Cells, Immunocytochemistry, Antineoplastic Agents, Biology, methods, Pathology and Forensic Medicine, medicine, Biomarkers, Tumor, Humans, RNA, Messenger, Molecular Biology, Aged, Lasers, Carcinoma, Cell Biology, medicine.disease, Gemcitabine, Pancreatic Neoplasms, Thiazoles, Cancer research, RNA, pharmacology, analogs /&/ derivatives/pharmacology

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1344b44d30fd842a64f19505ec80a80Test
https://pubmed.ncbi.nlm.nih.gov/18490900Test